Elysium’s mission is to disrupt the $10B+ prescription opioid pain medications market by accomplishing what others thought impossible – to create a new class of opioid pain relievers that protect individuals from oral misuse, abuse, and fatal overdose (that is, from the simultaneous ingestion of multiple pills). Elysium’s technologies are designed to (i) enhance the ability of pain patients and physicians to employ effective opioid-based pain management, (ii) reduce the costly impact of prescription drug abuse on families and our economy; and (iii) save lives.
Our competitors primarily employ simple physics to develop formulations that make it more difficult for hardcore abusers to tamper with opioids to inhale and inject them. In contrast, we used chemistry to create a new class of opioids that offer superior tamper resistance while also leveraging the body’s natural digestive process to achieve a highly sought-after target product profile to self-attenuate the systemic exposures of an active opioid depending on the number of pills ingested (see ). Our O2P opioids are designed to provide the following unprecedented features:
lysium has innovated a novel molecular deactivation (XpiRx or “expiring pill”) technology designed to offer first-in-class diversion-resistance to effectively curb the widespread stockpiling, diversion, abuse, and overdose of unused prescription opioids, even by the most common route of abuse, oral ingestion. As depicted in Figure 2, XpiRx opioids are designed to provide the following unprecedented features:
Give customers a reason to do business with you.
Protects Against the Primary Route of Abuse
Please email and we will respond back shortly.
9000 Crow Canyon Road, Suite 620, Danville, CA 94506, us
Monday - Friday: 9am - 5pm
Saturday - Sunday: Closed